Ron Leuty

NGM Biopharmaceuticals inks diabetes drug deal with AstraZeneca

bizjournals.com — Jun 17, 2013, 10:30am PDT NGM Biopharmaceuticals Inc. will work with MedImmune, owned by giant AstraZeneca PLC, on drugs aimed at diabetes and obesity. South San Francisco-based NGM will contribute elements of its enteroendocrine cell, or ECC, program to the collaboration.

NGM Biopharmaceuticals inks diabetes drug deal with AstraZeneca

bizjournals.com — Jun 17, 2013, 10:30am PDT NGM Biopharmaceuticals Inc. will work with MedImmune, owned by giant AstraZeneca PLC, on drugs aimed at diabetes and obesity. South San Francisco-based NGM will contribute elements of its enteroendocrine cell, or ECC, program to the collaboration.

Eshoo, Markey Welcome FDA Tightening of Security Standards for Medical Devices

eshoo.house.gov — Official website for Representative Anna G. Eshoo (CA-14), representing the heart of Silicon Valley in Congress, including parts of San Mateo, Santa Clara and Santa Cruz Counties. Eshoo currently serves as Ranking Member on the Communications and Technology Subcommittee.

CALBIO2013: Success Redefined

calbio2013.com — California. The birthplace of the biotechnology industry and home to the largest and most productive concentration of life science companies in the world. Over the years, our focus has remained constant - discover the next great thing and turn it into reality.

Statement On U.S. Supreme Court Review Of Isolated DNA Patents

bio.org — June 13, 2013 Washington, D.C. (June 13, 2013) Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO), today issued the following statement on the U.S. Supreme Court's decision regarding Myriad Genetics' patent claims on isolated DNA molecules: "The Supreme Court today summarily ruled that so-called cDNA remains eligible for patenting.

The FDA wants tighter cybersecurity for medical devices, and companies may have to supply cybersecurity data as part of the product approval process. Too much? Or not enough? | LinkedIn

linkedin.com — As concerns about the hackability of medical devices mount around the world, the FDA is proposing tighter regulations for manufacturers, suggesting that companies include cybersecurity information along with clinical data when...

Article • American Gastroenterological Association (AGA)

gastro.org — Article Screening At-Risk Adolescents for Celiac Disease Proves Cost-Effective and Successful in Preventing Bone Disease Bethesda, MD (June 10, 2013) - The current standard practice of screening adolescents who are either symptomatic or at high-risk for celiac disease proves to be more cost-effective than universal screening.

VICTORY! Supreme Court Decides: Our Genes Belong to Us, Not Companies

aclu.org — Should companies be able to patent human genes? Today, the Supreme Court answered that profound question with a resounding NO. Seems like common sense, right? But over the last 30 years, the U.S. Patent Office has issued patents on thousands of human genes, including genes associated wit...